Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick O Brien

Physical Medicine & Rehabilitation Raleigh, NC Medical Doctor

NPI 1356374219 CMS profile 242462

3000 New Bern Ave, Raleigh, NC 27610

Open in the dashboard

General payments

$85,665

179 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick O Brien of Raleigh, NC is reported in the CMS Open Payments database as having received $85,665 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,427 13
2024 General $4,683 40
2023 General $10,927 27
2022 General $21,554 15
2021 General $24,815 14
2020 General $4,464 15
2019 General $10,795 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick O Brien
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Patrick O Brien were reported at $8,427. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Patrick O Brien Physical Medicine & Rehabilitation median Middle half National median
2019 $10,795 $133 $45–$390 $163
2020 $4,464 $88 $29–$272 $114
2021 $24,815 $116 $33–$360 $132
2022 $21,554 $123 $40–$378 $149
2023 $10,927 $131 $43–$396 $160
2024 $4,683 $141 $45–$409 $164
2025 $8,427 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $46,518 43 payments
  2. AbbVie, Inc. $36,797 45 payments
  3. Medtronic, Inc. $477 6 payments
  4. Janssen Pharmaceuticals, Inc $268 12 payments
  5. Otsuka America Pharmaceutical, Inc. $204 9 payments
  6. Sunovion Pharmaceuticals Inc. $197 14 payments
  7. UCB, Inc. $149 5 payments
  8. Microtransponder, Inc. $131 1 payment
  9. Neurocrine Biosciences, Inc. $122 2 payments
  10. Avanir Pharmaceuticals, Inc. $122 6 payments
  11. Other $680 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $78,646 29 payments
  2. Food and Beverage $3,516 137 payments
  3. Travel and Lodging $3,488 11 payments
  4. Education $15 2 payments
Products named General payments · program years 2019–2025
  1. BOTOX Neuroscience $72,641 46 payments
  2. BOTOX Neuroscience $10,064 11 payments
  3. BOTOX Botox Therapeutic $478 16 payments
  4. SYNCHROMEDII $438 4 payments
  5. XARELTO $268 12 payments
  6. REXULTI $140 6 payments
  7. INGREZZA $122 2 payments
  8. NUEDEXTA $122 6 payments
  9. BOTOX Hyperhydrosis $116 14 payments
  10. APTIOM $116 9 payments
  11. Other $1,188 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 385 drugs

Part D claims

91,676

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$4,957,231

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

19.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 3,453 $891,912
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 71 $294,550
Ingrezza Valbenazine Tosylate Brand 21 $179,986
Trulicity Dulaglutide Brand 336 $177,877
Xarelto Rivaroxaban Brand 500 $130,363
Jardiance Empagliflozin Brand 404 $104,111
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 171 $102,344
Tradjenta Linagliptin Brand 534 $99,676
Nuplazid Pimavanserin Tartrate Brand 51 $97,927
Entresto Sacubitril/Valsartan Brand 286 $86,043

The 10 drugs with the highest cost, of 385 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$834,141

Of which drugs: $585,811

Medicare patients

846

Average age 74

Services billed

123,548

440 women, 406 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 46%
Chronic kidney disease 45%
Depression 44%
Ischemic heart disease 42%
Heart failure 37%
Atrial fibrillation 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 116 116,500 $567,705

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $3,943
$3,943 — 116,500
REXULTI
  • Otsuka America Pharmaceutical, Inc. $74
  • Lundbeck LLC $49
$123 20 —
INGREZZA
  • Neurocrine Biosciences, Inc. $100
$100 21 —
VALTOCO
  • Neurelis, Inc. $85
$85 — —
Nayzilam
  • UCB, Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record